Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pierfranco Ioan is active.

Publication


Featured researches published by Pierfranco Ioan.


Current Medicinal Chemistry | 2012

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets

Emanuele Carosati; Pierfranco Ioan; M. Micucci; Fabio Broccatelli; Gabriele Cruciani; Boris S. Zhorov; A. Chiarini; Roberta Budriesi

1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. Then medicinal chemists decorated the 1,4-DHP nucleus, the most studied scaffold among L-type calcium channel blockers, achieving diverse activities at several receptors, channels and enzymes. We already described (Ioan et al. Curr. Med. Chem. 2011, 18, 4901-4922) the effects of 1,4-DHPs at ion channels and G-protein coupled receptors. In this paper we continue the analysis of the wide range of biological effects exerted by compounds belonging to this chemical class. In particular, focus is given to the ability of 1,4-DHPs to revert multi drug resistance that, after over 20 years of research, continues to be of great interest. We also describe activities on other targets and the action of 1,4-DHPs against several diseases. Finally, we report and review the interaction of 1,4-DHPs with the hERG channel, transporters and phase I metabolizing enzymes. This work is a starting point for further exploration of the 1,4-DHP core activities on targets, off-targets and antitargets.


Current Medicinal Chemistry | 2011

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 1): Action in Ion Channels and GPCRs

Pierfranco Ioan; Emanuele Carosati; M. Micucci; Gabriele Cruciani; Fabio Broccatelli; Boris S. Zhorov; A. Chiarini; Roberta Budriesi

Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers have attracted large interest due to their effectiveness in treating several cardiovascular diseases. Medicinal chemists achieved high potency and tissue selectivity by decorating the 1-4-DHP nucleus, the most studied scaffold among LTCC blockers. Nowadays it is clear that the 1,4-DHP nucleus is a privileged scaffold since, when appropriately substituted, it can selectively modulate diverse receptors, channels and enzymes. Therefore, the 1,4-DHP scaffold could be used to treat various diseases by a single-ligand multi-target approach. In this review, we describe the structure-activity relationships of 1,4-DHPs at ion channels, G-protein coupled receptors, and outline the potential for future therapeutic applications.


Journal of Medicinal Chemistry | 2011

Cystic Fibrosis: A New Target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines

Roberta Budriesi; Pierfranco Ioan; Alberto Leoni; Nicoletta Pedemonte; Alessandra Locatelli; Matteo Micucci; Alberto Chiarini; Luis J. V. Galietta

The pharmacology of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl– channel has attracted significant interest in recent years with the aim to search for rational new therapies for diseases caused by CFTR malfunction. Mutations that abolish the function of CFTR cause the life-threatening genetic disease cystic fibrosis (CF). The most common cause of CF is the deletion of phenylalanine 508 (ΔF508) in the CFTR chloride channel. Felodipine, nifedipine, and other antihypertensive 1,4-dihydropyridines (1,4-DHPs) that block L-type Ca2+ channels are also effective potentiators of CFTR gating, able to correct the defective activity of ΔF508 and other CFTR mutants (Mol. Pharmacol.2005, 54, 1736). For this purpose, we evaluated the ability of the previously and newly synthesized 4-imidazo[2,1-b]thiazoles-1,4-dihydropyridines without vascular activity and inotropic and/or chronotropic cardiac effects (J. Med. Chem.2008, 54, 1592) to enhance the activity of ΔF508-CFTR. Our studies indicate compounds 17, 18, 20, 21, 38, and 39 as 1,4-DHPs with an interesting profile of activity.


Journal of Medicinal Chemistry | 2009

Novel, potent, and selective quinoxaline-based 5-HT3 receptor ligands. 1. Further structure-activity relationships and pharmacological characterization

Stefania Butini; Roberta Budriesi; Michel Hamon; Elena Morelli; Sandra Gemma; Margherita Brindisi; Giuseppe Borrelli; Ettore Novellino; Isabella Fiorini; Pierfranco Ioan; Alberto Chiarini; Alfredo Cagnotto; Tiziana Mennini; Claudia Fracasso; Silvio Caccia; Giuseppe Campiani

We investigated the pharmacological profile of a novel series of quinoxaline-based 5-HT(3) receptor ligands bearing an extra basic moiety on the piperazine N-4. High affinity and selectivity were dependent on the electronic properties of the substituents, and at cardiac level 3a and 3c modulated chronotropy but not inotropy. In von Bezold-Jarisch reflex test 3a-c were partial agonists while 3i was a full agonist. Preliminary pharmacokinetic studies indicated that 3a is a brain penetrating agent.


Bioorganic & Medicinal Chemistry | 2003

Cardiovascular hybrid drugs: new benzazepinone derivatives as bradycardic agents endowed with selective β1-Non-competitive antagonism

Alessandra Bisi; Angela Rampa; Roberta Budriesi; Silvia Gobbi; Federica Belluti; Pierfranco Ioan; Ermanno Valoti; Alberto Chiarini; Piero Valenti

The synthesis and pharmacological profile of some hybrid compounds bearing both the benzazepinone moiety present in Zatebradine and typical beta-blocker aryloxypropanolamine groups are described. The new compounds proved to be endowed with negative chronotropic and inotropic activity and are weak vasorelaxant agents. The cardiodepressant action is probably due to selective beta(1)-noncompetitive reversible antagonism. Both enantiomers of the most active compound 5c were synthesized and they showed a different cardiovascular profile, that is (+)-(R)-enantiomer displays affinity for cardiac beta(1)-adrenoceptors, while (-)-(S)-enantiomer shows specificity for vessel smooth muscle.


Journal of Medicinal Chemistry | 2013

Ligand based approach to L-type calcium channel by imidazo[2,1-b]thiazole-1,4-dihydropyridines: from heart activity to brain affinity.

Alessandra Locatelli; Sandro Cosconati; Matteo Micucci; Alberto Leoni; Luciana Marinelli; Andrea Bedini; Pierfranco Ioan; Santi Spampinato; Ettore Novellino; Alberto Chiarini; Roberta Budriesi

The synthesis, characterization, and functional in vitro assay in cardiac and smooth muscle (vascular and nonvascular) of a series of 4-imidazo[2,1-b]thiazole-1,4-dihydropyridines are reported. To define the calcium blocker nature of the imidazo[2,1-b]thiazole-1,4-DHPs and their selectivity on Cav1.2 and Cav1.3 isoforms, we performed binding studies on guinea pig atrial and ventricular membranes on intact cells expressing the cloned Cav1.2a subunit and on rat brain cortex. To get major insights into the reasons for the affinity for Cav1.2 and/or Cav1.3, molecular modeling studies were also undertaken. Some physicochemical and pharmacokinetic properties of selected compounds were calculated and compared. All the biological data collected and reported herein allowed us to rationalize the structure-activity relationship of the 4-imidazo[2,1-b]thiazole-1,4-DHPs and to identify which of these enhanced the activity at the central level.


Journal of Medicinal Food | 2010

Stop Fitan: Antispasmodic Effect of Natural Extract of Chestnut Wood in Guinea Pig Ileum and Proximal Colon Smooth Muscle

Roberta Budriesi; Pierfranco Ioan; Matteo Micucci; Ermanno Micucci; Vittorio Limongelli; Alberto Chiarini

Abstract Stop Fitan® [manufactured by Demar Snc, Cesena (FC), Italy, on behalf of Geosilva, Cesena] is a dietary supplement proposed as a co-adjuvant in the therapy of diarrhea. It is based on the bioactive purified natural extract of chestnut (Castanea sativa) wood and Saccharomyces boulardii, a nonpathogenic yeast strain that has been used for treatment and prevention of diarrhea. The effects of Stop Fitan and the purified natural extract of chestnut wood were assessed in vitro using guinea pig ileum and proximal colon tissues. In order to explain their effects on intestinal smooth muscle contraction, a series of pathways implicated in intestinal motility have been investigated. In particular, the antispasmodic effect of natural extract of chestnut wood, containing hydrolyzable tannins, was tested against the spasmodic effects induced by carbachol, histamine, potassium chloride, and barium chloride in guinea pig ileum and by carbachol or serotonin in guinea pig proximal colon. The data show that natural extract of chestnut wood exerts spasmolytic effects in ileum and proximal colon, by a mechanism perhaps involving unspecific cellular pathways. These findings, taken together with the antibacterial, antiviral, and antispasmodic properties of tannins, suggest that the combination of tannins and S. boulardii may be relevant to treat diarrhea by Stop Fitan.


Investigational New Drugs | 2011

Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis.

Maurizio Viale; Cinzia Cordazzo; Daniela de Totero; Roberta Budriesi; Camillo Rosano; Alberto Leoni; Pierfranco Ioan; Cinzia Aiello; Michela Croce; Aldo Andreani; Mirella Rambaldi; Patrizia Russo; Alberto Chiarini; Domenico Spinelli

SummaryWe report herein the reversal of multidrug resistance-1 (MDR1) in A2780/DX3 cells by the two nifedipine-like compounds 1 and 2 that are part of a library of 1,4-dihydropyridines (1,4-DHPs) calcium-channel modulators bearing in C-4 a different substituted imidazo[2,1-b]thiazole system. By methylthiazol tetrazolium (MTT) assay, cytofluorimetry, and fluorescence microscopy we evaluated their ability to reverse MDR in our cell system. Moreover, together with compound 3 (the diltiazem-like 8-(4-chlorophenyl)-5-methyl-8-[(2Z)-pent-2-en-1-yloxy]-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one) we analyzed their ability to potentiate the triggering of apoptosis after exposure to doxorubicin, through the nuclear morphological analysis after 4′,6-diamidino-2-phenylindole (DAPI), the fluorescein isothiocyanate (FITC)-Annexin-V/propidium iodide (PI) staining and the caspase activity determination. Our results demonstrate that compounds 1 and 2, at concentrations showing a very low (5%) or absent inhibition of cell proliferation, in combination with doxorubicin enhance its antiproliferative activity (from 30% to 54% IC50 reduction) in A2780/DX3 cells through an increase of doxorubicin intracellular accumulation. These compounds together with compound 3, which has already been demonstrated to act as a potent inhibitor of MDR1 function, were also able to significantly potentiate the activation of the apoptosis machinery triggered by the exposure to doxorubicin. In conclusion, our results identify two new molecules structurally related to the calcium-channel blocker nifedipine, but characterized by a very low LTCC blockers activity, able to potentiate the antiproliferative and apoptotic activities of doxorubicin through an increase of its intracellular concentration likely caused by the inhibition of MDR1 function.


Journal of Medicinal Chemistry | 2009

Specific targeting of peripheral serotonin 5-HT3 receptors. Synthesis, biological investigation, and structure-activity relationships

Elena Morelli; Sandra Gemma; Roberta Budriesi; Giuseppe Campiani; Ettore Novellino; Caterina Fattorusso; Bruno Catalanotti; Salvatore Sanna Coccone; Sindu Ros; Giuseppe Borrelli; Vinod Kumar; Marco Persico; Isabella Fiorini; Vito Nacci; Pierfranco Ioan; Alberto Chiarini; Michel Hamon; Alfredo Cagnotto; Tiziana Mennini; Claudia Fracasso; Milena Colovic; Silvio Caccia; Stefania Butini

The synthesis and the biological characterization of novel highly selective pyrroloquinoxaline 5-HT(3) receptor (5-HT(3)R) ligands are described. In functional and in vivo biological studies the novel quinoxalines modulated cardiac parameters by direct interaction with myocardial 5-HT(3)Rs. The potent 5-HT(3)R ligands 4h and 4n modulate chronotropy (right atrium) but not inotropy (left atrium) at the cardiac level, being antagonist and partial agonist, respectively. Preliminary pharmacokinetic studies indicate that (S)-4n and 4a, representatives of the novel 5-HT(3)R ligands, possess poor blood-brain barrier permeability, being the prototypes of peripherally acting 5-HT(3)R modulators endowed with a clear-cut pharmacological activity at the cardiac level. The unique properties of 4h and 4n, compared to their previously described centrally active N-methyl analogue 5a, are mainly due to the hydrophilic groups at the distal piperazine nitrogen. These analogues represent novel pharmacological tools for investigating the role of peripheral 5-HT(3)R in the modulation of cardiac parameters.


Oxidative Medicine and Cellular Longevity | 2013

Sweet Chestnut (Castanea sativa Mill.) Bark Extract: Cardiovascular Activity and Myocyte Protection against Oxidative Damage

Alberto Chiarini; Matteo Micucci; Marco Malaguti; Roberta Budriesi; Pierfranco Ioan; Monia Lenzi; Carmela Fimognari; Tullia Gallina Toschi; Patrizia Comandini; Silvana Hrelia

This work was aimed at evaluating the cardioprotective effects of Castanea sativa Mill. (CSM) bark extract characterized in its phenolic composition by HPLC-DAD-MS analysis. The study was performed using primary cultures of neonatal rat cardiomyocytes to investigate the antioxidant and cytoprotective effects of CSM bark extract and isolated guinea pig left and right atria, left papillary muscle, and aorta to evaluate its direct effect on cholinergic and adrenergic response. In cultured cardiomyocytes the CSM bark extract reduced intracellular reactive oxygen species formation and improved cell viability following oxidative stress in dose-dependent manner. Moreover, the extract decreased the contraction induced by noradrenaline (1 μM) in guinea pig aortic strips and induced transient negative chronotropic and positive inotropic effects without involvement of cholinergic or adrenergic receptors in the guinea pig atria. Our results indicate that CSM bark extract exhibits antioxidant activity and might induce cardioprotective effect.

Collaboration


Dive into the Pierfranco Ioan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barbara Cosimelli

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ettore Novellino

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge